Making cell-free DNA testing accessible to all healthcare providers
Categories: News
Published: 29 July 2026

Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Join Forces to Expand the Application of Advanced Genomic Technologies in Cancer Care

Progress in precision oncology does not happen through innovation alone. It is built on scientific evidence, clinical collaboration, and a shared commitment to improving patient outcomes.

 Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

With this vision in mind, on 27 July, Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital signed a Memorandum of Understanding (MOU) to strengthen collaboration in advancing genomic technologies for cancer care in Vietnam.
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation
Speaking at the signing ceremony, Dr. Nguyen Huu Nguyen, Co-founder and Deputy Chief Executive Officer of Gene Solutions, said:
“Through this partnership, Gene Solutions aims to further advance precision medicine in clinical practice while building an integrated ecosystem that connects clinical and genomic data, bringing innovative technologies closer to physicians, patients, and healthcare systems.”
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation
Echoing this shared commitment, Dr. Diep Bao Tuan, Director of Ho Chi Minh City Oncology Hospital, highlighted the hospital’s vision of strengthening early cancer detection through integrated screening approaches before specialized diagnostic investigations. He also noted the potential of SPOT-MAS 10, which has received U.S. FDA Breakthrough Device Designation*, to expand access to efficient and evidence-based multi-cancer screening in the future.
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

We sincerely thank Ho Chi Minh City Oncology Hospital for its trust and partnership. Together, we look forward to bringing high-quality genomic technologies to more patients across Vietnam and generating robust evidence from local populations, strengthening the foundation for broader adoption of precision medicine across Asia.

Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Advanced Genomic Technologies in Cancer Care MCED SPOTMAS 10 US.FDA Breakthrough Device Designation

Learn more about our solutions: https://genesolutions.com/our-solutions

Learn more about SPOT-MAS 10: https://genesolutions.com/our-test/spot-mas

*Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization. SPOT-MAS 10 remains subject to future FDA review.